|Day Low/High||164.07 / 167.99|
|52 Wk Low/High||90.14 / 196.00|
Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.
Look for this name to jump quickly in popularity in 2018 as investors players search for a convenient way to play the marijuana niche.
Consumers in California eagerly await the end to it prohibition on the recreational use of cannabis.
- Previous License Agreement with Otsuka Terminated -
Party leaders will have to work toward merging the two versions of tax reform into one final bill.
From tax cuts to the Flynn fallout, Jim Cramer says investors have to be covered.
Over 20 abstracts released online today from Phase 3 programs in Lennox-Gastaut Syndrome and Dravet syndrome and from Expanded Access Program
The Emeryville, Calif.-based firm said its first Phase 3 study of ZX008 in Dravet syndrome achieved its primary endpoint. Dravet syndrome is a form of epilepsy.
Jim Cramer is bearish on Iconix Brands, Kinder Morgan, Snap and GW Pharmaceuticals.
From political signals to the rebuilding and recovery efforts in Texas, Jim Cramer says investors should pay attention to what's supporting stocks.
Evercore ISI analyst Josh Schimmer is bullish on biotech.
Jim Cramer is bearish on Snap-On, Teekay Shipping, FLIR Systems, and GW Pharmaceuticals.
Jim Cramer says last week's selloff played out just like he predicted, and you haven't missed the sale.
Stocks can be a good gifts for individuals since they can be instrumental in wealth creation and demonstrate the power of compounding.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.